Abstract:Objective: To investigate the expression of long noncoding RNA urothelial carcinoembryonic antigen 1(UCA1) in patients with epithelial ovarian cancer(EOC) and its clinical significance. Methods: Ovarian tissue of 30 benign ovarian disease patients and 66 EOC patients were collected. UCA1 expression level was examined by realtime quantitative PCR. The diagnostic value of UCA1 expression was analyzed by ROC curve. The patients with EOC was divided into UCA1high and UCA1low expression group according to ROC method; and the clinicopathological parameters were analyzed. KaplanMeier analysis was used to determine the effect of UCA1 expression on survival time. Results: UCA1 expression of EOC patients was significantly upregulated than that of patients with benign ovarian disease(P<0.05). ROC analysis revealed UCA1 expression could distinguish EOC from benign ovarian disease with the AUC of 0.838(95%CI: 0.749-0.927, P<0.05). Abnormal expression of UCA1 was associated with FIGO stage, tumor differentiation and lymph node metastasis(P<0.05). Patients with highUCA1expression had a significantly shorter overall survival time and diseasefree survival time than patients with lowUCA1expression (P=0.004,0.037, respectively). Conclusion: Overexpression of UCA1 was observed in EOC, and it could be served as a poor prognostic biomarker in EOC.
收稿日期: 2017-08-14
作者简介: 谭歆(1985—),女,江苏镇江人,主治医师,硕士,主要从事妇科肿瘤疾病的研究。
引用本文:
谭歆. 尿路上皮癌胚抗原1在卵巢癌组织中的表达及临床意义[J]. 江苏大学学报:医学版, 2018, 28(01): 61-64.
TAN Xin. Expression of urothelial carcinoembryonic antigen 1 in epithelial ovarian cancer and its clinical significance. Journal of Jiangsu University(Medicine Edition), 2018, 28(01): 61-64.
1]Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012\[J\]. CA Cancer J Clin, 2015, 65(2): 87-108.[2]Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation\[J\]. Nat Rev Cancer, 2009, 9(6): 415-428.[3]Li C, Liang G, Yang S, et al. Dysregulated lncRNAUCA1 contributes to the progression of gastric cancer through regulation of the PI3KAktmTOR signaling pathway\[J\]. Oncotarget, 2017, 8(55):93476-93491.[4]Cai Q, Jin L, Wang S, et al. Long noncoding RNA UCA1 promotes gallbladder cancer progression by epigenetically repressing p21 and Ecadherin expression\[J\]. Oncotarget, 2017, 8(29):47957-47968.[5]Li D, Li H, Yang Y, et al. Long noncoding RNA urothelial carcinoma associated 1 promotes the proliferation and metastasis of human lung tumor cells by regulating microRNA144\[J\]. Oncol Res, 2017. \[Epub ahead of print\].[6]Yang Y, Jiang Y, Wan Y, et al. UCA1 functions as a competing endogenous RNA to suppress epithelial ovarian cancer metastasis\[J\]. Tumour Biol, 2016, 37(8): 10633-10641.[7]Wang F, Zhou J, Xie X, et al. Involvement of SRPK1 in cisplatin resistance related to long noncoding RNA UCA1 in human ovarian cancer cells\[J\]. Neoplasma, 2015, 62(3):432-438.[8]Xue M, Chen W, Li X. Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer\[J\]. J Cancer Res Clin Oncol, 2016, 142(7): 1407-1419.[9]He A, Hu R, Chen Z, et al. Role of long noncoding RNA UCA1 as a common molecular marker for lymph node metastasis and prognosis in various cancers: a metaanalysis\[J\]. Oncotarget, 2017, 8(1):1937-1943.[10]Zhang L, Cao X, Zhang L, et al. UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy\[J\]. Cancer Chemother Pharmacol, 2016, 77(3):629-634.[11]Wang H, Guan Z, He K, et al. LncRNA UCA1 in anticancer drug resistance\[J\]. Oncotarget, 2017, 8(28): 64638-64650.[12]Jiao C, Song Z, Chen J, et al. lncRNAUCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer\[J\]. Oncol Rep, 2016, 36(5): 2960-2966.[13]Qian Y, Liu D, Cao S, et al. Upregulation of the long noncoding RNA UCA1 affects the proliferation, invasion, and survival of hypopharyngeal carcinoma\[J\]. Mol Cancer, 2017, 16(1):68.[14]Wen JJ, Ma YD, Yang GS, et al. Analysis of circulating long noncoding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma\[J\]. Eur Rev Med Pharmacol Sci, 2017, 21(3):498-503.